Sanofi (NASDAQ:SNY) Shares Sold by GAMMA Investing LLC

GAMMA Investing LLC lessened its position in Sanofi (NASDAQ:SNY) by 17.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,816 shares of the company’s stock after selling 816 shares during the period. GAMMA Investing LLC’s holdings in Sanofi were worth $184,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of SNY. Barrow Hanley Mewhinney & Strauss LLC raised its position in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares in the last quarter. Federated Hermes Inc. lifted its stake in Sanofi by 26.5% during the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after purchasing an additional 673,172 shares during the last quarter. Finally, Natixis Advisors LLC boosted its holdings in Sanofi by 4.1% during the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after buying an additional 114,133 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SNY. Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Sanofi has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Down 1.3 %

SNY stock opened at $49.23 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market capitalization of $124.94 billion, a P/E ratio of 25.12, a P/E/G ratio of 1.23 and a beta of 0.57. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The company’s 50 day simple moving average is $48.87 and its 200-day simple moving average is $52.09.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company’s revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.55 EPS. As a group, equities research analysts anticipate that Sanofi will post 4.06 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.